Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature Medicine 8, 500 - 508 (2002)
doi:10.1038/nm0502-500
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
Christopher Lock1,9, Guy Hermans1,9, Rosetta Pedotti1,9, Andrea Brendolan2,9, Eric Schadt4, Hideki Garren1, Annette Langer-Gould1, Samuel Strober2, Barbara Cannella7, John Allard8, Paul Klonowski8, Angela Austin8, Nagin Lad8, Naftali Kaminski6, Stephen J. Galli3, Jorge R. Oksenberg5, Cedric S. Raine7, Renu Heller8 & Lawrence Steinman1
Abstract
Microarray analysis of multiple sclerosis (MS) lesions obtained at autopsy revealed increased transcripts of genes encoding inflammatory cytokines, particularly interleukin-6 and -17, interferon-
and associated downstream pathways. Comparison of two poles of MS pathology—acute lesions with inflammation versus 'silent' lesions without inflammation—revealed differentially transcribed genes. Some products of these genes were chosen as targets for therapy of experimental autoimmune encephalomyelitis (EAE) in mice. Granulocyte colony-stimulating factor is upregulated in acute, but not in chronic, MS lesions, and the effect on ameliorating EAE is more pronounced in the acute phase, in contrast to knocking out the immunoglobulin Fc receptor common
chain where the effect is greatest on chronic disease. These results in EAE corroborate the microarray studies on MS lesions. Large-scale analysis of transcripts in MS lesions elucidates new aspects of pathology and opens possibilities for therapy.
To read this story in full you will need to login or make a payment (see right).
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REVIEWS NEWS AND VIEWS RESEARCH |
